Difluprednate ophthalmic

Drug Profile

Difluprednate ophthalmic

Alternative Names: Durezol; SJE-2079; ST-601

Latest Information Update: 05 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Senju Pharmaceutical
  • Developer Alcon; Senju Pharmaceutical; Sirion Therapeutics
  • Class Anti-inflammatories; Fluorinated steroids; Pregnadienetriols
  • Mechanism of Action Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ocular inflammation; Ocular pain; Uveitis
  • Phase II Diabetic macular oedema
  • No development reported Dry eyes

Most Recent Events

  • 28 Jul 2016 Senju Pharmaceutical completes a phase II trial for Diabetic macular oedema in Japan (UMIN000011873)
  • 03 Aug 2015 Difluprednate ophthalmic is still in phase II trials for Diabetic macular oedema in Japan
  • 07 Oct 2013 No development reported - Phase-II for Dry eyes in USA (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top